

## Epcoritamab ELISA Kit

Catalogue No.: abx395064

This product is currently in development. The lead time for this product may be several months. Please contact us at [info@abbexa.com](mailto:info@abbexa.com) for an updated lead time before purchasing this product.

This product is currently in development. The lead time for this product may be several months. Please contact us at [info@abbexa.com](mailto:info@abbexa.com) for an updated lead time before purchasing this product.

Epcoritamab ELISA Kit is a quantitative ELISA kit for detection of Epcoritamab.

Epcoritamab (DuoBody-CD3xCD20, GEN3013) is a novel bispecific IgG1 antibody redirecting T-cells toward CD20+ tumor cells. Here, we assessed the preclinical efficacy of epcoritamab against primary tumor cells present in the lymph node biopsies from newly diagnosed (ND) and relapsed/refractory (RR) B-NHL patients. In the presence of T-cells from a healthy donor, epcoritamab demonstrated potent activity against primary tumor cells, irrespective of prior treatments, including CD20 mAbs. Median lysis of 65, 74, and 84% were achieved in diffuse large B-cell lymphoma (n = 16), follicular lymphoma (n = 15), and mantle cell lymphoma (n = 8), respectively. Furthermore, in this allogeneic setting, we discovered that the capacity of B-cell tumors to activate T-cells was heterogeneous and showed an inverse association with their surface expression levels of the immune checkpoint molecule Herpesvirus Entry Mediator (HVEM). In the autologous setting, when lymph node (LN)-residing T-cells were the only source of effector cells, the epcoritamab-dependent cytotoxicity strongly correlated with local effector cell-to-target cell ratios. Further analyses revealed that LN-residing-derived or peripheral blood-derived T-cells of B-NHL patients, as well as healthy donor T-cells equally mediated epcoritamab-dependent cytotoxicity. These results show the promise of epcoritamab for treatment of newly-diagnosed or relapsed/refractory B-NHL patients, including those who became refractory to previous CD20-directed therapies.

**Target:** Epcoritamab

**Research Area:** Biosimilars

**Reactivity:** Human

**Tested Applications:** ELISA

**Recommended dilutions:** Optimal dilutions/concentrations should be determined by the end user.

**Storage:** Shipped at 4 °C. Upon receipt, store the kit according to the storage instruction in the kit's manual.

**Validity:** The validity for this kit is 6 months.

**Stability:** The stability of the kit is determined by the rate of activity loss. The loss rate is less than 5% within the expiration date under appropriate storage conditions. To minimize performance fluctuations, operation procedures and lab conditions should be strictly controlled. It is also strongly suggested that the whole assay is performed by the same user throughout.

**Test Range:** 0.31 µg/ml - 5 µg/ml

# Datasheet

Version: 5.0.0  
Revision date: 27 Jun 2025



**Sensitivity:** 0.16 µg/ml

**Standard Form:** Lyophilized

**Detection Method:** Colorimetric

**Assay Type:** Competitive

**Assay Data:** Quantitative

**Sample Type:** Serum and plasma.

**CAS Number:** 2134641-34-0

**Note:** THIS PRODUCT IS FOR RESEARCH USE ONLY. NOT FOR USE IN DIAGNOSTIC OR THERAPEUTIC PROCEDURES.

The range and sensitivity is subject to change. Please contact us for the latest product information.

For accurate results, sample concentrations must be diluted to mid-range of the kit. If you require a specific range, please contact us in advance or write your request in your order comments.

Please note that our kits are optimised for detection of native samples, rather than recombinant proteins. We are unable to guarantee detection of recombinant proteins, as they may have different sequences or tertiary structures to the native protein.